Skip to main content

Table 1 Baseline characteristics and clinical outcomes of the included patients

From: The impact of COVID-19 critical illness on new disability, functional outcomes and return to work at 6 months: a prospective cohort study

 

Hospital cohort (n = 212)

Follow-up cohorta

(n = 160)

Age, years

61 (51–70)

62 (55–71)

 < 60

99 (46.7)

69 (43.1)

60–69

54 (25.5)

43 (26.9)

70–79

48 (22.6)

39 (24.4)

 > 80

11 (5.2)

9 (5.6)

Male gender—no. (%)

124 (58.5)

97 (60.6)

APACHE II

14 (10–19)

15 (11–19)

Days between symptoms—hospital admission

6.1 (3.6–9.2)

6.4 (3.4–9.2)

Days between symptoms—ICU admission

8.1 (5.3–11.0)

8.1 (5.4–11.0)

Body mass index, kg/m2

29.4 (25.0–35.7)

30.0 (25.5–35.8)

Clinical frailty score

3 (2–3)

3 (2–3)

Years of education

14 (11–16)

14 (11–16)

Healthcare worker—no. (%)

24/205 (11.7)

15/153 (9.8)

Coexisting disorders—no. (%)

  

Diabetes

67/206 (32.5)

56/154 (36.4)

Obesity

60/200 (30.0)

48/151 (31.8)

Use of ACEi or ARB

38/198 (19.2)

31/148 (20.9)

Chronic cardiac failure

35/202 (17.3)

29/152 (19.1)

Smoker

25/197 (12.7)

18/148 (12.2)

Chronic pulmonary disease**

16/201 (8.0)

14/153 (9.2)

Asthma

28/202 (13.9)

18/153 (11.8)

Immunosuppression

24/202 (11.9)

20/152 (13.2)

Chronic kidney disease

14/203 (6.9)

12/153 (7.8)

Chronic hematological disease

9/202 (4.5)

8/152 (5.3)

Cancer

12/203 (5.9)

11/153 (7.2)

Symptoms—no. (%)

  

Fever

159/204 (77.9)

119/152 (78.3)

Cough

143/204 (70.1)

108/152 (71.1)

Shortness of breath

135/204 (66.2)

101/152 (66.4)

Fatigue

106/204 (52.0)

81/152 (53.3)

Myalgia

73/204 (35.8)

63/152 (41.4)

Diarrhea

59/204 (28.9)

42/152 (27.6)

Sore throat

46/204 (22.5)

35/152 (23.0)

Anosmia

22/204 (10.8)

16/152 (10.5)

Runny nose

22/204 (10.8)

17/152 (11.2)

Signs at baseline

  

Heart rate, bpm

100 (85–110)

99 (85–110)

Respiratory rate, breaths/min

30 (24–38)

30 (24–38)

Mean arterial pressure, mmHg

81 (70–96)

81 (70–97)

Temperature, °C

38.3 (37.4–38.9)

38.2 (37.4–38.8)

SpO2, %

92 (88–95)

92 (88–95)

Clinical outcomes

  

Hospital readmission—no. (%)

–

18/108 (16.7)

Duration of ventilation, days

12 (5–19)

13 (5–19)

ICU length of stay, days

6.9 (3.2–17.1)

8.3 (3.6–19.0)

Hospital length of stay, days

16.1 (9.6–26.7)

16.9 (10.1–30.4)

ICU mortality—no. (%)

39 (18.4)

39 (24.4)

Hospital mortality—no. (%)

42/211 (19.9)

42 (26.2)

Death or new disability at 6 months—no. (%)

–

85/151 (56.3)

  1. Data are median (quartile 25%–quartile 75%) or no (%). Percentages may not total 100 because of rounding
  2. APACHE Acute Physiology and Chronic Health Evaluation, ACEi angiotensin-converting enzyme inhibitor, ARB angiotensin II receptor blocker, ICU intensive care unit
  3. aThe follow-up cohort comprises patients who died within 6 months or who were contacted successfully at 6 months. However, data may be missing for some outcomes depending on the willingness of the patient to answer all questions
  4. *On a scale from 1 to 10 (1 would be the lowest level of financial distress)
  5. **Not considering asthma
Back to article page

Critical Care

ISSN: 1364-8535